AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 22 min read$GILD

O'Day Daniel Patrick sold $405K of GILD

O'Day Daniel Patrick (Chairman & CEO) sold 3,062 shares of GILEAD SCIENCES, INC. (GILD) at $132.22 ($0.40M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · O'Day Daniel Patrick
Published Jun 2, 2026, 10:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GILD
Neutral
medium confidence
Mentioned
$GILD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GILDNeutralLow
01

Why it matters

The disclosure provides incremental sentiment information but does not introduce new company fundamentals (no earnings, trial, guidance, deal, or regulatory event).

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 pre-arrangement reduces the likelihood of a durable negative reprice.

03

What to watch

Insider sales can cluster around scheduled plans; without additional filings (e.g., buys, option exercises, or changes in plan size), signal-to-noise is low.

Relevance 6/10Novelty 3/10Timing: Filed 2026-06-02 after the 2026-06-01 sale under a 10b5-1 plan.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO/Chairman under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$GILDNeutralMedium confidence
Context

Gilead CEO/Chairman O’Day sold $404.8K of GILD shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief unless accompanied by other news.

Evidence & confidence

The filing is a routine insider transaction with stated 10b5-1 pre-arrangement, providing disclosure but not a new operational or financial catalyst.

Market effects

Sector

Minimal; this is company-specific insider disclosure without sector-wide catalyst.

Regional

Minimal; US-listed large-cap disclosure unlikely to drive broader regional flows.

Global

Minimal; no international transaction or regulatory action described.

Counterpoint

What could challenge this read

Because the sale is pre-arranged, it may be more about liquidity/tax planning than bearish expectations; the market may overreact.

Key entities

  • issuer
    Gilead Sciences, Inc.

    Subject of the insider transaction disclosure (Form 4) involving CEO/Chairman O’Day.

  • insider
    O’Day Daniel Patrick

    CEO/Chairman who sold 3,062 shares at $132.2151 on 2026-06-01 under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$GILDMed

Weekly HIV Pill Held Viral Suppression as Well as Daily Therapy in Phase 3 Trial

Phase 3 ISLEND-1 results in the New England Journal of Medicine found a once-weekly tablet of islatravir 2 mg plus lenacapavir 300 mg was noninferior to once-daily bictegravir, emtricitabine, and tenofovir alafenamide for maintaining HIV viral suppression at 48 weeks in 607 adults already suppressed for at least 6 months. None on weekly therapy had HIV-1 RNA ≥50 copies/mL vs 0.3% on daily. Serious adverse events were 5.3% vs 4.6%.

medicaldaily.com7 min
AUG 7
$GILDMedAI 8/10

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences (GILD) reported Q2 2026 non-GAAP loss per share of $6.75 and revenue of $7.8B, both above consensus. Management raised 2026 product sales guidance excluding Veklury to $29.8B-$30.1B and lifted HIV sales growth outlook to 9%-10%. CEO cited HIV and PrEP strength, Trodelvy growth, and ongoing anito-cel launch prep.

zacks.com6 min
AUG 6
$MRKMed

MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data

Merck & Co (MSD) and Gilead Sciences ended the Phase III KEYNOTE-D46/EVOKE-03 trial in frontline PD-L1-expressing NSCLC after an external data monitoring committee projected the Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) would not significantly improve overall survival versus Keytruda alone. Trodelvy-Keytruda showed nonsignificant PFS benefit and no new safety issues. Trodelvy Q2 2026 sales rose 26% to $457m.

yahoo.com3 min
AUG 5
$GILDMed

GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure

Gilead Sciences (GILD) reported Q2 CY2026 revenue of $7.80 billion, up 10.2% year over year, and a non-GAAP loss of $6.75 per share. Full-year revenue guidance was $30.25 billion at the midpoint, 0.6% below analysts’ estimates. Management cited HIV franchise strength, including Biktarvy and PrEP, plus Trodelvy growth, while noting margin pressure from acquisition-related R&D costs.

stockstory.org4 min